Intensivmedizin up2date, Table of Contents Intensivmedizin up2date 2017; 13(01): 67-87DOI: 10.1055/s-0042-122812 Neuro-Intensivmedizin © Georg Thieme Verlag KG Stuttgart · New YorkNicht-Vitamin-K orale Antikoagulanzien in der Klinik Authors Corina Epple Johannes Rosskopp Thorsten Steiner Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) In den letzten Jahren werden NOAC zunehmend eingesetzt. Sie sind eine sichere und effektive Alternative zu den etablierten Vitamin-K-Antagonisten und weisen auch außerhalb der Studien weniger Blutungskomplikationen auf. Die wachsende Erfahrung mit den NOAC zeigt jedoch, dass noch Verbesserungsbedarf besteht und weitere Studien dringend erforderlich sind. Full Text References Literatur 1 Patel NJ, Deshmukh A, Pant S. et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 2014; 129: 2371-2379 2 Rizos T, Wagner A, Jenetzky E. et al. Paroxysmal atrial fibrillation is more prevalent than persistent atrial fibrillation in acute stroke and transient ischemic attack patients. Cerebrovascular Diseases (Basel, Switzerland) 2011; 32: 276-282 3 Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurology 2012; 11: 1066-1081 4 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis 2007; 98: 756-764 5 Reilly PA, Lehr T, Haertter S. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-328 6 Holbrook A, Schulman S, Witt DM. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e152S-e184S 7 Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994; 120: 897-902 8 Franke CL, de Jonge J, van Swieten JC. et al. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21: 726-730 9 Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Thrombolysis 2010; 29: 182-191 10 Heidbuchel H, Verhamme P, Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651 11 Steiner T, Bohm M, Dichgans M. et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clinical Research in Cardiology 2013; 102: 399-412 12 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetics 2008; 47: 285-295 13 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis 2010; 103: 1116-1127 14 Mueck W, Eriksson BI, Bauer KA. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clinical Pharmacokinetics 2008; 47: 203-216 15 Harenberg J, Erdle S, Marx S. et al. Determination of rivaroxaban in human plasma samples. Seminars in Thrombosis and Hemostasis 2012; 38: 178-184 16 Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013; 121: 4032-4035 17 Kitchen S, Gray E, Mackie I. et al. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J of Haematology 2014; 166: 830-841 18 Rizos T, Herweh C, Jenetzky E. et al. Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009; 40: 3547-3551 19 Ebner M, Peter A, Spencer C. et al. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants. Stroke 2015; 46: 2741-2747 20 van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012; 125: 417-420 21 Härtig F, Peter A, Spencer C. et al. Specific Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants Part I (SPOCT-NOAC I). Stroke 2016; 47: A164 22 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-746 23 Pernod G, Albaladejo P, Godier A. et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) March 2013. Archives of Cardiovascular Diseases 2013; 106: 382-393 24 Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Seminars in Neurology 2010; 30: 565-572 25 Dowlatshahi D, Butcher KS, Asdaghi N. et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817 26 Flibotte JJ, Hagan N, O‘Donnell J. et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63: 1059-1064 27 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 28 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104 29 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992 30 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891 31 Epple C, Steiner T. Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. Expert Opinion on Pharmacotherapy 2014; 15: 1991-2001 32 Hart RG, Diener HC, Yang S. et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517 33 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599 34 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778 35 Purrucker JC, Haas K, Rizos T. et al. Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants. JAMA Neurology 2016; 73: 169-177 36 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thrombosis and Haemostasis 2012; 108: 217-224 37 Frontera JA, Lewin 3rd JJ, Rabinstein AA. et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Crit Care Med. Neurocritical Care 2016; 24: 6-46 38 Khadzhynov D, Wagner F, Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thrombosis and Haemostasis 2013; 109: 596-605 39 Vigue B, Ract C, Tremey B. et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33: 721-725 40 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England) 2014; 383: 955-962 41 May A, Farber M, Aschmoneit I. et al. Prospective multicenter trial comparing push-and-pull enteroscopy with the single- and double-balloon techniques in patients with small-bowel disorders. Am J of Gastroenterology 2010; 105: 575-581 42 Lim LG, Ho KY, Chan YH. et al. Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Endoscopy 2011; 43: 300-306 43 Liew A, Eikelboom JW, O'Donnell M. et al. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. The Canadian Journal of Cardiology 2013; 29 (Suppl. 07) S34-44 44 Seet RC, Zhang Y, Moore SA. et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011; 42: 2333-2335 45 Steiner T, Poli S, Griebe M. et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurology 2016; 15: 566-573 46 Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thrombosis and Haemostasis 2015; 113: 931-942 47 Pollack Jr CV, Reilly PA. et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520 48 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine 2013; 19: 446-451 49 Crowther MA, Levy G, Lu G. et al. ANNEXA™-A: A Phase 3 Randomized,Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. AHA presentation Nov 2014. Circulation 2014; 130: 2105-2126 50 O‘Riordan M. Positive Results for Factor Xa Inhibitor Antidote: ANNEXA-A. 2014 Im Internet: http://www.medscapecom/viewarticle/832648 [Stand: 07.04.2016 51 Connolly SJ, Milling Jr TJ, Eikelboom JW. et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2016; 375: 1131-1141 52 Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 2016; 18: 955-964 53 Ansell JE, Bakhru SH, Laulicht BE. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371: 2141-2142 54 Laulicht B, Bakhru S, Jiang X. et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Amsterdam: 24th Congress of the International Society on Thrombosis and Haematosis; 2013 55 Kuramatsu JB, Gerner ST, Schellinger PD. et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824-836 56 Ansell J. Is there a need for an alternative in the era of novel anticoagulants?. Expert Review of Cardiovascular Therapy 2015; 13: 967-970
